Experience of managing menopausal symptoms and quality of sleep with melatonin

Melatonin is one of the most underestimated agents of the endocrine system. While remaining undeservedly in the shadow of clinical science, it adjusts the body to the systemic changes of the external and internal environment. The periods of perimenopause and menopause are characterized by high levels of stress and reduced quality of life. In recent years, there is a growing understanding that melatonin as adaptogenic hormone supports the female body in this particularly vulnerable period of life. We assessed secretion of melatonin in women with climacteric syndrome (CS) and the effect of melatonin therapy on menopausal symptoms and quality of sleep. The study involved 31 women (mean age 53.5 ± 4,1 years) with mild CS (average age of menopause 52 ± 3 years). Melatonin secretion was evaluated by the concentration of its metabolite (urinary 6-hydroxy-melatonin-sulfate) using enzyme immunoassay. All patients received melatonin 3 mg/day orally at bedtime for 3 months. The results of the treatment were clinically assessed using the modified menopausal index (MMI) and the Pittsburgh Sleep Quality Index (PSQI). We found that baseline 6-hydroxy-melatonin-sulfate levels were very low in the evening urine: 1.88 ng/ml (1.08 to 5.34); at night and in the early morning they moderately increased (up to 6.36 ng/ml [from 2,34 to 16,04] and 25.71 ng/ml [15.51 to 32.03], respectively). After 1 month of treatment, MMI in the subjects decreased from 24,9 ± 8,1 points to 16,6 ± 8,8 (P = 0.013) and further to 13,2 ± 6,3 points after 3 months (P = 0.001). The MMI demonstrated a significant decrease of neuro-vegetative symptoms. The median PSQI decreased from 9 to 2 points (p = 0,027). Our findings suggest that melatonin is able to inhibit mild CS and the associated sleep disturbances.

мелатонин, 6-сульфатоксимелатонин, постменопауза, климактерический синдром, сон, melatonin, 6-hydroxy-melatonin-sulfate, postmenopause, climacteric syndrome, sleep

1. Анисимов В.Н., Виноградова И.А. Старение женской репродуктивной системы и мелатонин. СПб.: Издательство «Система», 2008: 44 с.

2. Медицина климактерия. Под ред. В.П. Смет-ник. Ярославль: ООО «Издательство Литера», 2006. 848 с.

3. Karasek M, Winczyk K. Melatonin in human. Journal of physiology and pharmacology, 2006, 57(5): P. 19-39.

4. Мальцева Л.И., Гафарова Е.А., Гарипова ПХ. Роль мелатонина в регуляции функции половых желез и возможности его применения в лечении симптомов патологического климакса. Успехи геронтологии, 2007, 20(4): 68-74.

5. Анисимов В.Н., Хавинсон В.Х., Морозов В.Г. Роль пептидов эпифиза в регуляции гомео-стаза: 20-летний опыт исследования. Успехи современной биологии, 1993, 113(6.): 752-762.

6. Рагозин О.Н., Бочкарев М.В. Влияние измененного фотопериодизма северного региона на биологические ритмы человека в норме и патологии. Руководство по хронобиологии и хрономедицине. М., 2012: 119-136.

7. Анисимов В.Н. Молекулярные и физиологические механизмы старения: В 2 т. 2-е изд., перераб. и доп. СПб.: Наука, 2008. Т. 2. 434 с.

8. Анисимов В.Н. Мелатонин - роль в организме, применение в клинике. СПб.: Изд-во «Система», 2007. 40 с.

9. Bondarenko LA, Sotnik NN, Gevorkyan AR. Role of melatonin in the mechanisms underlying neuroendocrine control of the hypothalamo-hypophyseal-thyroid axis. Neurophysiology, 2008, 40(5-6): 393-403.

10. Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. International Journal of Molecular Sciences, 2014, 15(10): 17920-17937.

11. Kozirog M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. Journal of Pineal Research, 2011, 50 (3): 261-266.

12. Gonciarz M, Gonciarz Z, Bielanski W, Mularczyk A, Konturek PC, Brzozowski T, Konturek SI. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: A pilot study. Journal of Physiology and Pharmacology, 2012, 63(1): 35-40.

13. Maria, S., Witt-Enderby, PA. Melatonin effects on bone: Potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures. Journal of Pineal Research, 2014, 56(2): 115-125.

14. Man'cheva TA, Demidov DV, Plotnikova NA, Kharitonova TV, Pashkevich IV, Anisimov VN. Melatonin and metformin inhibit skin carcinogenesis and lipid peroxidation induced by Benz(a)pyr-ene in female mice. Bulletin of Experimental Biology and Medicine, 2011, 151(3): 363-365.

15. Damien L, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in Insomnia and its relation to the response to melatonin replacement therapy. The American Journal of Medicine, 2004, 116(2): 91-95.

16. Anisimov V.N., Vinogradova I.A. Aging of the female reproductive system and melatonin. SPb: Sistema, 2008: 44 p.

17. Anisimov V.N., Khavinson V.K., Morozov V.G. The role of the pineal gland peptids in the regulation of homeostasis: a 20 year-study. Uspekhi Sovremennoy Biologii, 1993, 113(6.): 752-762.

18. Ragozin O.N., Bochkarev M.V. Effect of modified photoperiodism in the northern region on biological rhythms in human in health and disease. Guidance on chronobiology and chronomedicine. М.: 2012: 119-136.

19. Anisimov V.N. Molecular and physiological mechanisms of aging: In 2 vol. 2nd ed., rev. and enl. Spb.: Nauka, 2008. V. 2. 434 p.

20. Anisimov V.N. Melatonin: the role in the body, clinical use. SPb: Sistema, 2007. 40 p.

21. Medicine of menopause. Ed. by V.P. Smetnik. Yaroslavl: Litera, 2006. 848 p.

22. Maltseva L.I., Gafarova E.A., Garipova G.K. The role of melatonin in the regulation of gonadal function and potential for its use in the treatment of pathological symptoms of menopause. Uspekhi Gerontologii, 2007, 20 (4): 68-74.